Estimation of the occurrence rates of IDH1 and IDH2 mutations in gliomas and the reconsideration of IDH -wildtype anaplastic astrocytomas: an institutional experience.

Objectives: Most diffuse gliomas are reported to harbor isocitrate dehydrogenase ( IDH ) mutations. However, when these mutations are tested in clinical practice, the results are often negative.
Methods: This study examined the frequency of IDH1 and IDH2 mutations in gliomas classified according to the revised 2016 World Health Organization classification, and investigated their prognostic relevance. We tested 87 gliomas for IDH1 and IDH2 mutations using the peptide nucleic acid clamp method.
Results: IDH1 mutations were observed in 42% of diffuse astrocytomas, 23% of anaplastic astrocytomas, all oligodendrogliomas and anaplastic oligodendrogliomas, and 17% of glioblastomas. An IDH2 mutation was identified in one case of diffuse astrocytoma. In the survival analysis of diffuse astrocytic tumors, patients with IDH1/2 -wildtype anaplastic astrocytomas tended to have a poor prognosis, similar to that of glioblastomas.
Conclusions: IDH2 mutations were infrequent in gliomas. In anaplastic astrocytomas, the frequency of IDH1/2 -wildtype was relatively high, and the prognosis of patients with this type of tumor was very similar to that of those with glioblastomas. It may therefore be necessary to reconsider the classification and treatment strategies for IDH1/2 -wildtype anaplastic astrocytomas.